Arthur A. Levin - Jun 24, 2021 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Chief Scientific Officer
Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Stock symbol
RNA
Transactions as of
Jun 24, 2021
Transactions value $
-$545,215
Form type
4
Date filed
6/28/2021, 07:21 PM
Previous filing
Jun 22, 2021
Next filing
Nov 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $124 +100 +7.52% $1.24* 1.43K Jun 24, 2021 Direct F1
transaction RNA Common Stock Sale -$2.78K -100 -6.99% $27.76 1.33K Jun 24, 2021 Direct F1
transaction RNA Common Stock Options Exercise $21.1K +17K +1279.47% $1.24* 18.3K Jun 25, 2021 Direct F1
transaction RNA Common Stock Options Exercise $1.63K +3.08K +16.8% $0.53* 21.4K Jun 25, 2021 Direct F1
transaction RNA Common Stock Sale -$488K -17.5K -81.44% $27.97 3.98K Jun 25, 2021 Direct F1, F2
transaction RNA Common Stock Sale -$77.1K -2.65K -66.56% $29.14 1.33K Jun 25, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -100 -0.05% $0.00 208K Jun 24, 2021 Common Stock 100 $1.24 Direct F1, F4
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -17K -8.17% $0.00 191K Jun 25, 2021 Common Stock 17K $1.24 Direct F1, F4
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -3.08K -6.79% $0.00 42.3K Jun 25, 2021 Common Stock 3.08K $0.53 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.80 to $28.71. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.22. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.
F5 This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly.